CliffBio
biologic

Creon

pancrelipase

Loss of exclusivityJune 2023projected — 12-year biologic exclusivity estimate
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameCreon
Active ingredientpancrelipase
Strength3,000USP UNITS; 9,500USP UNITS; 15,000USP UNITS
Dosage formCapsule, Delayed Release
RouteOral
ModalityBiologic
FDA approvalJune 2011
Marketing statusRx

More from AbbVie Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Creon patent cliff — loss of exclusivity June 2023 | CliffBio